Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy VKTX Stock  Free VKTX Stock Alerts

Viking Therapeutics (VKTX) Financials

Viking Therapeutics logo
$28.16 +1.03 (+3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$28.22 +0.06 (+0.21%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Viking Therapeutics

Annual Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -110 -86 -69 -55 -79 -26 -22 -21 -15 -23
Consolidated Net Income / (Loss)		 -110 -86 -69 -55 -39 -26 -22 -21 -15 -23
Net Income / (Loss) Continuing Operations		 -110 -86 -69 -55 -79 -26 -22 -21 -15 -23
Total Pre-Tax Income 		-110 -86 -69 -55 -79 -26 -22 -21 -15 -23
Total Operating Income		 -151 -101 -70 -56 -43 -33 -26 -19 -14 -12
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 151 101 70 56 85 33 26 19 14 12
Selling, General & Admin Expense		 49 37 16 11 11 9.13 7.12 5.33 4.85 5.03
Research & Development Expense		 102 64 54 45 32 24 19 14 9.00 6.97
Amortization Expense		 0.09 0.09 0.06 0.02 - - - - - -
Total Other Income / (Expense), net		 41 15 1.55 0.71 6.33 6.91 4.10 -1.51 -0.88 -11
Interest & Investment Income		 41 15 1.59 0.70 3.23 7.05 3.24 0.00 -0.02 -0.09
Other Income / (Expense), net		 0.11 0.00 -0.04 0.01 3.10 -0.15 1.27 -0.23 0.93 -10
Basic Earnings per Share		 ($1.01) ($0.91) ($0.90) ($0.71) ($0.54) ($0.36) ($0.38) ($0.79) ($0.90) ($3.68)
Weighted Average Basic Shares Outstanding		 109.04M 94.35M 76.83M 77.20M 72.60M 71.96M 57.58M 25.98M 16.28M 6.36M
Diluted Earnings per Share		 ($1.01) ($0.91) ($0.90) ($0.71) ($0.54) ($0.36) ($0.38) ($0.79) ($0.90) ($3.68)
Weighted Average Diluted Shares Outstanding		 109.04M 94.35M 76.83M 77.20M 72.60M 71.96M 57.58M 25.98M 16.28M 6.36M
Weighted Average Basic & Diluted Shares Outstanding		 112.25M 100.49M 78.42M 77.20M 72.60M 71.96M 57.58M 25.98M 16.28M 6.36M

Quarterly Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Consolidated Net Income / (Loss)		 -46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Net Income / (Loss) Continuing Operations		 -46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Total Pre-Tax Income 		-46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Total Operating Income		 -55 -46 -37 -34 -34 -29 -27 -24 -21 -20 -16
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 55 46 37 34 34 29 27 24 21 20 16
Selling, General & Admin Expense		 14 15 14 10 9.97 8.78 8.89 9.82 9.53 4.11 4.24
Research & Development Expense		 41 31 23 24 24 21 18 14 11 16 12
Amortization Expense		 0.02 - 0.02 - 0.03 - 0.00 - 0.03 - 0.03
Total Other Income / (Expense), net		 9.86 11 12 12 6.75 4.74 4.73 4.52 1.03 0.59 0.45
Interest & Investment Income		 9.86 11 12 12 6.75 4.71 4.73 4.55 1.03 0.73 0.45
Other Income / (Expense), net		 0.00 0.02 0.11 -0.02 0.00 0.03 0.00 -0.03 0.00 -0.14 0.00
Basic Earnings per Share		 ($0.41) ($0.33) ($0.22) ($0.20) ($0.26) ($0.24) ($0.23) ($0.19) ($0.25) ($0.25) ($0.21)
Weighted Average Basic Shares Outstanding		 112.07M 109.04M 110.91M 110.39M 103.46M 94.35M 99.85M 99.01M 78.35M 76.83M 76.51M
Diluted Earnings per Share		 ($0.41) ($0.33) ($0.22) ($0.20) ($0.26) ($0.24) ($0.23) ($0.19) ($0.25) ($0.25) ($0.21)
Weighted Average Diluted Shares Outstanding		 112.07M 109.04M 110.91M 110.39M 103.46M 94.35M 99.85M 99.01M 78.35M 76.83M 76.51M
Weighted Average Basic & Diluted Shares Outstanding		 112.31M 112.25M 111.44M 110.80M 110.27M 100.49M 100.03M 100.03M 99.58M 78.42M 76.69M

Annual Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -29 19 11 -2.75 21 -16 7.40 5.91 2.31 0.01
Net Cash From Operating Activities		 -88 -73 -48 -48 -22 -25 -19 -15 -11 -8.73
Net Cash From Continuing Operating Activities		 -88 -73 -48 -48 -22 -25 -19 -15 -11 -8.73
Net Income / (Loss) Continuing Operations		 -110 -86 -69 -55 -39 -26 -22 -21 -15 -23
Consolidated Net Income / (Loss)		 -110 -86 -69 -55 -39 -26 -22 -21 -15 -23
Amortization Expense		 -17 -7.82 1.57 4.22 4.19 1.02 1.26 2.94 2.08 1.03
Non-Cash Adjustments To Reconcile Net Income		 31 17 9.37 7.29 8.40 5.49 1.21 1.11 0.73 13
Changes in Operating Assets and Liabilities, net		 8.16 3.23 9.58 -4.10 5.13 -5.49 0.82 1.77 0.85 0.62
Net Cash From Investing Activities		 -553 -179 55 38 42 7.46 -266 -1.73 3.03 -13
Net Cash From Continuing Investing Activities		 -553 -179 55 38 42 7.46 -266 -1.73 3.03 -13
Purchase of Investments		 -1,113 -478 -121 -168 -281 -362 -348 -23 -17 -16
Sale and/or Maturity of Investments		 560 299 176 206 322 370 82 21 20 2.56
Net Cash From Financing Activities		 612 271 4.16 6.88 0.95 0.89 300 22 10 22
Net Cash From Continuing Financing Activities		 612 271 4.16 6.88 0.95 0.89 292 22 10 22
Repurchase of Common Equity		 0.00 0.00 -6.80 0.00 -0.03 -0.07 - -0.50 -1.10 -2.78
Issuance of Common Equity		 11 6.77 0.85 7.63 1.27 1.11 297 23 12 25
Other Financing Activities, net		 602 265 10 -0.75 -0.30 -0.15 0.13 -0.02 -0.03 -0.42

Quarterly Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 11 -24 6.46 -152 140 18 -32 51 -18 7.08 13
Net Cash From Operating Activities		 -52 -31 -22 -29 -6.13 -18 -20 -11 -25 -11 -13
Net Cash From Continuing Operating Activities		 -52 -31 -22 -29 -6.13 -18 -20 -11 -25 -11 -13
Net Income / (Loss) Continuing Operations		 -46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Consolidated Net Income / (Loss)		 -46 -35 -25 -22 -27 -25 -23 -19 -20 -20 -16
Amortization Expense		 -3.00 -3.90 -4.87 -5.34 -2.72 -2.60 -3.07 -1.86 -0.29 0.03 0.31
Non-Cash Adjustments To Reconcile Net Income		 14 5.03 10 6.93 8.65 3.99 4.74 4.56 3.82 2.28 2.12
Changes in Operating Assets and Liabilities, net		 -18 3.10 -2.38 -7.86 15 5.58 1.21 5.09 -8.65 6.37 -0.15
Net Cash From Investing Activities		 63 6.58 26 -126 -460 36 -13 -204 2.20 7.26 27
Net Cash From Continuing Investing Activities		 63 6.58 26 -126 -460 36 -13 -204 2.20 7.26 27
Purchase of Investments		 -233 -137 -150 -230 -597 -98 -79 -244 -57 -45 -10
Sale and/or Maturity of Investments		 296 144 176 104 137 133 67 39 60 52 37
Net Cash From Financing Activities		 0.35 1.00 2.52 2.91 606 0.19 -0.07 267 4.18 11 0.01
Net Cash From Continuing Financing Activities		 0.35 1.00 2.52 2.91 606 0.19 -0.07 267 4.18 11 0.01
Issuance of Common Equity		 0.35 1.00 2.52 - - 0.19 -0.00 - - 0.15 -
Other Financing Activities, net		 0.00 - - -4.39 606 - -0.07 260 4.18 11 0.01

Annual Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 908 368 169 211 257 284 302 22 15 15
Total Current Assets		 907 367 167 211 256 284 302 22 14 15
Cash & Equivalents		 27 56 37 26 29 8.38 25 8.99 3.08 0.77
Short-Term Investments		 876 307 119 176 219 267 277 12 10 13
Prepaid Expenses		 1.13 5.15 12 8.43 7.72 7.86 0.61 1.28 0.82 1.10
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.05 1.16 1.49 0.13 0.40 0.76 0.18 0.27 0.56 0.24
Other Noncurrent Operating Assets		 1.05 1.16 1.49 0.13 0.40 0.76 0.18 0.27 0.56 0.24
Total Liabilities & Shareholders' Equity		 908 368 169 211 257 284 302 22 15 15
Total Liabilities		 28 20 23 8.78 12 7.14 4.56 8.66 6.49 6.71
Total Current Liabilities		 27 19 22 8.78 12 6.78 4.55 8.66 6.48 1.98
Accounts Payable		 9.81 7.51 8.53 1.44 3.99 2.43 0.96 1.53 1.20 0.59
Accrued Expenses		 17 11 13 7.31 7.81 4.04 3.59 2.26 1.24 1.38
Other Current Liabilities		 0.49 0.32 0.30 0.03 0.33 0.30 - 1.40 0.73 0.00
Total Noncurrent Liabilities		 0.63 0.94 1.26 0.00 0.06 0.36 0.01 0.00 0.02 4.74
Other Noncurrent Operating Liabilities		 0.63 0.94 1.26 0.00 0.03 0.36 - - - 2.55
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 880 348 145 202 244 277 298 13 8.04 8.72
Total Preferred & Common Equity		 880 348 145 202 244 277 298 13 8.04 8.72
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 881 349 145 202 244 277 298 13 8.04 8.72
Common Stock		 1,369 734 445 426 413 406 401 94 68 54
Retained Earnings		 -488 -378 -292 -223 -168 -129 -103 -81 -60 -46
Treasury Stock		 0.00 -6.80 -6.80 0.00 - - - - - -

Quarterly Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 867 938 947 968 383 401 151 167
Total Current Assets		 866 937 946 966 381 399 149 165
Cash & Equivalents		 38 50 44 196 37 70 18 29
Short-Term Investments		 814 880 898 767 339 323 117 126
Prepaid Expenses		 14 6.21 0.14 0.64 5.06 6.45 3.93 10
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.94 1.16 1.01 1.09 1.36 1.32 1.38 1.54
Other Noncurrent Operating Assets		 0.94 1.16 1.01 1.09 1.36 1.32 1.38 1.54
Total Liabilities & Shareholders' Equity		 867 938 947 968 383 401 151 167
Total Liabilities		 20 26 26 34 14 15 17 15
Total Current Liabilities		 20 26 25 33 13 13 16 14
Accounts Payable		 7.70 0.25 11 5.23 5.71 5.61 3.80 3.14
Accrued Expenses		 11 25 14 27 7.38 7.55 12 11
Other Current Liabilities		 0.50 0.48 0.33 0.33 0.32 0.31 0.31 0.30
Total Noncurrent Liabilities		 0.50 0.76 0.77 0.85 1.02 1.10 1.18 1.34
Other Noncurrent Operating Liabilities		 0.50 0.76 0.77 0.85 1.02 1.10 1.18 1.34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 847 911 921 934 368 386 134 151
Total Preferred & Common Equity		 847 911 921 934 368 386 134 151
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 847 910 923 935 368 386 135 151
Common Stock		 1,381 1,362 1,351 1,341 729 725 453 432
Retained Earnings		 -534 -452 -428 -405 -353 -331 -312 -272
Treasury Stock		 0.00 0.00 0.00 0.00 -6.80 -6.80 -6.80 -6.80

Annual Metrics And Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.29% -57.85% -33.77% -45.48% -11.19% -34.61% -44.51% -50.84% 49.33% -3.38%
EBIT Growth		 -49.57% -43.23% -26.44% -40.73% -20.49% -31.89% -29.02% -49.33% 42.37% -5.49%
NOPAT Growth		 -49.68% -43.31% -26.35% -30.52% -30.52% -24.95% -37.18% -37.72% -15.43% 48.88%
Net Income Growth		 -28.02% -24.73% -25.24% -39.23% -53.21% -16.84% -7.22% -39.68% 37.05% -6.94%
EPS Growth		 -10.99% -1.11% -26.76% -31.48% -50.00% 5.26% 51.90% 12.22% 75.54% 29.64%
Operating Cash Flow Growth		 -19.64% -51.61% -1.70% -118.51% 12.02% -31.98% -27.08% -33.30% -26.80% -448.66%
Free Cash Flow Firm Growth		 -39.67% -70.40% 8.17% -75.84% 13.48% -54.74% -57.90% -3.57% 61.23% 0.00%
Invested Capital Growth		 -87.90% -35.45% -4,540.64% 94.58% -372.92% 139.28% -3.63% -101.75% 44.13% 86.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.22% -11.79% -14.28% -38.64% 23.55% -4.95% -18.43% -3.31% 14.80% -35.32%
EBIT Q/Q Growth		 -12.68% -9.60% -12.43% -33.12% 20.38% -5.93% -15.02% -3.31% 11.18% -33.25%
NOPAT Q/Q Growth		 -12.65% -9.80% -12.42% -24.86% 14.87% -5.95% -11.09% -3.75% 5.99% -55.20%
Net Income Q/Q Growth		 -10.90% -6.24% -11.68% -2.63% -9.72% -9.38% -5.52% -2.19% 8.94% -38.29%
EPS Q/Q Growth		 -9.78% 1.09% -12.50% 0.00% -10.20% -20.00% 19.15% -6.76% 40.00% -36.80%
Operating Cash Flow Q/Q Growth		 -18.24% -10.07% 2.86% -16.86% 22.32% -57.78% 6.33% -11.16% 7.01% -48.67%
Free Cash Flow Firm Q/Q Growth		 -13.10% -11.60% 8.77% -44.05% 36.20% -47.10% 3.29% -15.21% -1.83% 0.00%
Invested Capital Q/Q Growth		 -35.62% -72.05% -171.88% 92.73% -167.51% 132.34% -78.76% 17.74% -16.37% -49.72%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.09% 100.10% 100.09% 100.03% 50.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 72.85% 85.10% 97.74% 98.74% 199.67% 78.52% 88.62% 106.64% 114.01% 104.38%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17.90% -34.79% -39.67% -24.65% -15.15% -8.97% -14.18% -191.36% -175.71% 349.22%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,899.52% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -17.92% -34.82% -39.67% -24.65% -15.15% -8.97% -14.18% -191.36% -175.71% 349.22%
Return on Equity Simple (ROE_SIMPLE)		 -12.49% -24.65% -47.39% -27.24% -16.16% -9.30% -7.41% -152.84% -183.17% -268.24%
Net Operating Profit after Tax (NOPAT)		 -106 -71 -49 -39 -30 -23 -18 -13 -9.69 -8.40
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.68% -5.92% -10.97% -7.11% -3.68% -1.00% -2.35% -53.65% -46.23% -225.13%
Return On Investment Capital (ROIC_SIMPLE)		 -12.00% -20.26% -33.89% - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -151 -101 -70 -56 -40 -33 -25 -19 -13 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -168 -109 -69 -51 -35 -32 -24 -16 -11 -21
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 5.09 5.34 4.96 1.78 1.68 2.09 1.84 8.59 2.98 3.78
Price to Tangible Book Value (P/TBV)		 5.09 5.34 4.96 1.78 1.68 2.09 1.84 8.59 2.98 3.78
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 205.21 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.26 0.41 0.25
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25
Financial Leverage		 -1.03 -1.05 -1.03 -1.01 -1.00 -1.00 -1.02 -1.25 -1.30 0.99
Leverage Ratio		 1.04 1.09 1.09 1.05 1.04 1.02 1.04 1.70 1.79 -1.38
Compound Leverage Factor		 0.76 0.93 1.07 1.03 2.07 0.80 0.92 1.82 2.04 -1.44
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 20.40% 28.90% 19.78%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.40% 28.90% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 19.78%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.09% 100.11% 100.00% 100.00% 99.99% 100.00% 100.00% 79.60% 71.10% 80.22%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.30 -0.10
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 7.02 0.00 0.00 1.05 0.91 0.56
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26 -0.34 -0.26
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 8.32 0.00 0.00 1.28 1.02 1.42
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26
Altman Z-Score		 95.81 54.44 15.87 23.39 19.98 48.88 72.33 0.74 -5.90 -4.95
Noncontrolling Interest Sharing Ratio		 -0.10% -0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 33.09 19.19 7.61 23.98 21.12 41.83 66.40 2.52 2.16 7.69
Quick Ratio		 32.93 18.92 7.08 23.02 20.48 40.67 66.27 2.38 2.03 7.13
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -94 -67 -39 -43 -24 -28 -18 -12 -11 -29
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -45.00 -8.97 -6.22 -32.10
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -46.42 -11.50 -6.19 -9.77
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -46.42 -11.50 -6.19 -9.77
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -26 -14 -10 -0.22 -4.04 1.48 -3.77 -3.64 -1.80 -3.23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -12 -3.60 -9.94 3.82 -5.52 5.25 -0.13 -1.83 1.42 20
Enterprise Value (EV)		 3,582 1,499 565 158 162 304 245 99 14 21
Market Capitalization		 4,484 1,862 721 360 411 580 547 116 24 33
Book Value per Share		 $7.91 $3.49 $1.90 $2.58 $3.35 $3.83 $4.17 $0.47 $0.40 $0.90
Tangible Book Value per Share		 $7.91 $3.49 $1.90 $2.58 $3.35 $3.83 $4.17 $0.47 $0.40 $0.90
Total Capital		 880 348 145 202 244 277 298 17 11 11
Total Debt		 0.00 0.00 0.00 0.00 0.03 0.00 0.00 3.45 3.27 2.15
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 2.15
Net Debt		 -903 -362 -155 -202 -248 -276 -302 -17 -9.88 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -23 -14 -10 -0.35 -4.41 1.09 -3.94 -3.93 -2.38 -0.88
Debt-free Net Working Capital (DFNWC)		 880 348 145 202 244 277 298 17 11 13
Net Working Capital (NWC)		 880 348 145 202 244 277 298 13 7.50 13
Net Nonoperating Expense (NNE)		 4.32 15 20 16 9.63 2.90 3.75 7.23 5.04 15
Net Nonoperating Obligations (NNO)		 -906 -362 -155 -202 -248 -276 -302 -17 -9.85 -12
Total Depreciation and Amortization (D&A)		 -17 -7.82 1.57 4.22 4.19 1.02 1.26 2.94 2.08 1.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.01) ($0.91) ($0.90) ($0.71) ($0.54) ($0.36) ($0.38) ($0.79) ($0.90) ($3.68)
Adjusted Weighted Average Basic Shares Outstanding		 109.04M 94.35M 76.83M 78.36M 74.13M 72.56M 71.99M 50.90M 23.83M 9.68M
Adjusted Diluted Earnings per Share		 ($1.01) ($0.91) ($0.90) ($0.71) ($0.54) ($0.36) ($0.38) ($0.79) ($0.90) ($3.68)
Adjusted Weighted Average Diluted Shares Outstanding		 109.04M 94.35M 76.83M 78.36M 74.13M 72.56M 71.99M 50.90M 23.83M 9.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.71) ($0.54) ($0.36) ($0.38) ($0.79) ($0.90) ($3.68)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 112.25M 100.49M 78.42M 77.20M 72.60M 71.96M 57.58M 25.98M 16.28M 6.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -106 -71 -49 -39 -30 -23 -18 -13 -9.69 -8.40
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -61.62 -15.04 -7.23 -25.09
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -45.33 -10.40 -5.42 -9.40
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -61.62 -15.04 -7.23 -25.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -45.33 -10.40 -5.42 -9.40
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -9.87% 0.00% -0.07% -0.28% 0.00% -2.43% -7.44% -11.89%

Quarterly Metrics And Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -58.91% -57.33% -36.20% -53.76% -76.66% -56.17% -90.98% -48.99% -35.73% -72.88% -29.87%
EBIT Growth		 -62.79% -58.00% -33.68% -43.32% -65.91% -43.22% -68.34% -34.51% -27.54% -61.56% -22.30%
NOPAT Growth		 -62.79% -57.89% -34.08% -43.45% -65.91% -44.38% -68.34% -34.65% -26.42% -62.13% -20.84%
Net Income Growth		 -66.80% -43.94% -10.68% -15.73% -40.06% -25.80% -42.86% -10.29% -21.29% -58.30% -19.10%
EPS Growth		 -57.69% -37.50% 4.35% -5.26% -4.00% 4.00% -9.52% 17.39% -19.05% -66.67% -23.53%
Operating Cash Flow Growth		 -753.13% -76.76% -11.72% -149.35% 75.11% -61.45% -45.63% 14.93% -134.03% 11.53% -23.55%
Free Cash Flow Firm Growth		 -1,790.52% -19.95% 2.05% 56.06% 36.53% -297.18% -39.66% -13.08% 58.48% 66.18% -34.70%
Invested Capital Growth		 84.41% -87.90% -138.37% -263.13% -176.77% -35.45% -114.04% -84.57% -338.38% -4,540.64% -24.02%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -16.66% -21.30% -4.83% -7.12% -15.50% -5.01% -18.34% -23.08% -2.10% -28.42% 7.67%
EBIT Q/Q Growth		 -20.01% -26.81% -6.98% 0.01% -16.48% -7.29% -14.69% -15.75% -0.55% -26.11% 8.36%
NOPAT Q/Q Growth		 -19.96% -26.49% -7.35% 0.06% -16.35% -7.41% -14.85% -15.60% -1.25% -25.23% 8.14%
Net Income Q/Q Growth		 -28.83% -42.01% -12.09% 18.67% -11.18% -9.19% -17.21% 1.57% 0.14% -24.00% 9.52%
EPS Q/Q Growth		 -24.24% -50.00% -10.00% 23.08% -8.33% -4.35% -21.05% 24.00% 0.00% -19.05% 8.70%
Operating Cash Flow Q/Q Growth		 -67.83% -41.98% 22.98% -364.84% 65.23% 10.27% -71.91% 53.60% -125.54% 19.06% -0.42%
Free Cash Flow Firm Q/Q Growth		 -224.45% -39.59% -144.75% -70.55% 75.63% -13.99% -9.80% -146.35% -28.81% 59.92% 11.10%
Invested Capital Q/Q Growth		 80.78% -35.62% 22.82% 22.53% -94.62% -72.05% -17.58% 40.95% -13.40% -171.88% -1.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.05% 100.12% 100.10% 100.00% 100.10% 100.24% 100.01% 100.00% 100.14% 99.32% 100.17%
Interest Burden Percent		 82.22% 76.54% 68.36% 65.31% 80.20% 83.91% 82.64% 80.87% 94.97% 96.42% 97.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -14.40% -17.90% -15.50% -14.80% -17.55% -34.79% -31.12% -26.88% -45.71% -39.67% -33.84%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -14.42% -17.92% -15.48% -14.83% -17.59% -34.82% -31.12% -26.88% -45.80% -39.67% -33.84%
Return on Equity Simple (ROE_SIMPLE)		 -15.14% 0.00% -10.88% -10.50% -10.04% 0.00% -21.96% -19.19% -53.93% 0.00% -40.76%
Net Operating Profit after Tax (NOPAT)		 -39 -32 -26 -24 -24 -20 -19 -17 -14 -14 -11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.75% -0.48% 0.10% 0.24% -0.63% -1.59% -1.30% -0.93% -3.12% -3.00% -2.39%
Return On Investment Capital (ROIC_SIMPLE)		 -4.58% -3.68% - - - -5.88% - - - -9.77% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -55 -46 -36 -34 -34 -29 -27 -24 -21 -20 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -58 -50 -41 -39 -37 -32 -30 -26 -21 -20 -16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.20 5.09 7.71 6.33 8.77 5.34 3.01 4.18 9.69 4.96 1.38
Price to Tangible Book Value (P/TBV)		 3.20 5.09 7.71 6.33 8.77 5.34 3.01 4.18 9.69 4.96 1.38
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.02 -1.02 -1.04 -1.05 -1.02 -1.02 -1.04 -1.03 -1.02
Leverage Ratio		 1.03 1.04 1.03 1.03 1.05 1.09 1.06 1.06 1.09 1.09 1.07
Compound Leverage Factor		 0.85 0.80 0.71 0.67 0.84 0.91 0.87 0.85 1.04 1.05 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.03% 100.09% 99.82% 100.25% 100.17% 100.11% 100.00% 100.00% 100.46% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 81.12 96.19 159.54 136.04 146.81 55.08 45.69 66.24 44.27 16.84 6.61
Noncontrolling Interest Sharing Ratio		 -0.10% -0.10% 0.13% -0.17% -0.21% -0.08% 0.00% 0.00% -0.20% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 44.25 33.09 36.47 37.69 29.48 19.19 28.44 29.63 9.55 7.61 11.75
Quick Ratio		 43.52 32.93 36.23 37.55 29.38 18.92 28.07 29.15 8.67 7.08 11.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -66 -20 -15 -5.93 -3.48 -17 -15 -14 -5.48 -4.25 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.97 -26 -19 -25 -32 -14 -8.00 -6.81 -12 -10 -3.74
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 27 -12 -11 -18 -20 -3.60 -4.26 -3.12 -8.90 -9.94 -0.72
Enterprise Value (EV)		 1,859 3,582 6,084 4,903 7,239 1,499 731 1,221 1,170 565 54
Market Capitalization		 2,711 4,484 7,015 5,845 8,202 1,862 1,107 1,614 1,306 721 209
Book Value per Share		 $7.55 $7.91 $8.21 $8.37 $9.04 $3.49 $3.68 $3.88 $1.72 $1.90 $1.97
Tangible Book Value per Share		 $7.55 $7.91 $8.21 $8.37 $9.04 $3.49 $3.68 $3.88 $1.72 $1.90 $1.97
Total Capital		 847 880 911 921 934 348 368 386 134 145 151
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -852 -903 -930 -942 -963 -362 -376 -393 -136 -155 -155
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.41 -23 -19 -22 -29 -14 -8.35 -7.03 -1.85 -10 -3.94
Debt-free Net Working Capital (DFNWC)		 846 880 911 921 934 348 368 386 134 145 151
Net Working Capital (NWC)		 846 880 911 921 934 348 368 386 134 145 151
Net Nonoperating Expense (NNE)		 6.80 3.05 -0.65 -1.59 3.50 4.11 3.45 2.61 5.16 5.36 4.44
Net Nonoperating Obligations (NNO)		 -852 -906 -931 -946 -966 -362 -376 -393 -146 -155 -155
Total Depreciation and Amortization (D&A)		 -3.00 -3.90 -4.87 -5.34 -2.72 -2.60 -3.07 -1.86 -0.29 0.03 0.31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.41) ($0.33) ($0.22) ($0.20) ($0.26) ($0.24) ($0.23) ($0.19) ($0.25) ($0.25) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 112.07M 109.04M 110.91M 110.39M 103.46M 94.35M 99.85M 99.01M 78.35M 76.83M 76.51M
Adjusted Diluted Earnings per Share		 ($0.41) ($0.33) ($0.22) ($0.20) ($0.26) ($0.24) ($0.23) ($0.19) ($0.25) ($0.25) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 112.07M 109.04M 110.91M 110.39M 103.46M 94.35M 99.85M 99.01M 78.35M 76.83M 76.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 112.31M 112.25M 111.44M 110.80M 110.27M 100.49M 100.03M 100.03M 99.58M 78.42M 76.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -32 -26 -24 -24 -20 -19 -17 -14 -14 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.32% -9.87% -11.02%

Frequently Asked Questions About Viking Therapeutics' Financials

When does Viking Therapeutics's financial year end?

According to the most recent income statement we have on file, Viking Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Viking Therapeutics' net income changed over the last 9 years?

Viking Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.96 million in 2024, rising from -$23.40 million in 2015. The previous period was -$85.90 million in 2023. See where experts think Viking Therapeutics is headed by visiting Viking Therapeutics' forecast page.

What is Viking Therapeutics's operating income?
Viking Therapeutics's total operating income in 2024 was -$150.92 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $151.02 million
How has Viking Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2024, a change of 0.0%.

How much debt does Viking Therapeutics have?

Viking Therapeutics' total liabilities were at $28.04 million at the end of 2024, a 39.7% increase from 2023, and a 317.7% increase since 2015.

How much cash does Viking Therapeutics have?

In the past 9 years, Viking Therapeutics' cash and equivalents has ranged from $768.55 thousand in 2015 to $55.52 million in 2023, and is currently $26.68 million as of their latest financial filing in 2024.

How has Viking Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' book value per share changed from 0.90 in 2015 to 7.91 in 2024, a change of 777.0%.


Related Companies

This page (NASDAQ:VKTX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
As Bitcoin supply vanishes, this Trump-aligned token could explode
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...
Brownstone Research | Sponsored